Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?
Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.
Aim(s): To assess the efficacy and safety of TE in patients (pts) with SBNEN, with resistant-to-treatment flushing and diarrhoea.
Materials and methods: Seventeen SBNEN pts treated with oral TE 250mg tds were included. All had ongoing symptoms, despite maximum doses of long-acting SA +/- daily sc Octreotide injections. Frequency of bowel movements (BM) and flushing were assessed in 1, 6 and 12 months. Urinary 5HIAA levels were assessed at 6 or 12 months.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Gertner J
To read the full abstract, please log into your ENETS Member account.